Integrated Antibody Drug Discovery: Lead Generation, Characterization and Optimization
Therapeutic antibody drugs show significant growth rate. Within oncology research alone, more than 20 therapeutic antibody drugs received FDA approval for new treatments or indications during 2015 and 2016. In addition, more than 300 therapeutic antibody drugs are in ongoing clinical trials. Driven by the increase in biomarker discovery, more therapeutic antibody drugs are set to enter the market with increased competition. Therefore, to maximize the success of therapeutic antibody drug development, it is essential to thoroughly vet antibody drug candidates at every step of the process. Join this interactive webinar to learn more about therapeutic lead generation, lead characterization and lead optimization. We will discuss cutting edge high throughput screening platforms to guide hybridoma clone selection and examine characterization technologies required for rational selection of lead therapeutic antibody drug candidates. We will also review current platforms for lead optimization, including humanization and antibody affinity maturation. Ultimately, attendees will understand how these approaches integrate with both upstream and downstream therapeutic antibody drug discovery methodologies.
|Integrated Antibody Drug Discovery: Lead Generation, Characterization and Optimization|
|Antibody Humanization||DNA Immunization Service||Antibody Sequencing|